DE60001307D1 - Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung - Google Patents

Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung

Info

Publication number
DE60001307D1
DE60001307D1 DE60001307T DE60001307T DE60001307D1 DE 60001307 D1 DE60001307 D1 DE 60001307D1 DE 60001307 T DE60001307 T DE 60001307T DE 60001307 T DE60001307 T DE 60001307T DE 60001307 D1 DE60001307 D1 DE 60001307D1
Authority
DE
Germany
Prior art keywords
preparation
therapeutic uses
pyridopyranoazepine
derivatives
pyridopyranoazepine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60001307T
Other languages
English (en)
Other versions
DE60001307T2 (de
Inventor
Frederic Galli
Samir Jegham
Alistair Lochead
Axelle Samson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of DE60001307D1 publication Critical patent/DE60001307D1/de
Publication of DE60001307T2 publication Critical patent/DE60001307T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60001307T 1999-03-05 2000-03-01 Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung Expired - Lifetime DE60001307T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
PCT/FR2000/000502 WO2000053608A1 (fr) 1999-03-05 2000-03-01 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DE60001307D1 true DE60001307D1 (de) 2003-03-06
DE60001307T2 DE60001307T2 (de) 2003-12-11

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001307T Expired - Lifetime DE60001307T2 (de) 1999-03-05 2000-03-01 Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung

Country Status (37)

Country Link
US (2) US6538003B1 (de)
EP (1) EP1161434B1 (de)
JP (1) JP4806123B2 (de)
KR (2) KR20070086359A (de)
CN (1) CN1137894C (de)
AR (1) AR022820A1 (de)
AT (1) ATE231869T1 (de)
AU (1) AU764625B2 (de)
BG (1) BG65211B1 (de)
BR (1) BR0008763A (de)
CA (1) CA2372063C (de)
CO (1) CO5160250A1 (de)
CZ (1) CZ302259B6 (de)
DE (1) DE60001307T2 (de)
DK (1) DK1161434T3 (de)
EE (1) EE04497B1 (de)
ES (1) ES2191611T3 (de)
FR (1) FR2790474B1 (de)
HK (1) HK1040398B (de)
HR (1) HRP20010655B1 (de)
HU (1) HU228671B1 (de)
ID (1) ID30116A (de)
IL (2) IL145150A0 (de)
MX (1) MXPA01008972A (de)
NO (1) NO327119B1 (de)
NZ (1) NZ513561A (de)
PE (1) PE20001543A1 (de)
PL (1) PL201683B1 (de)
RS (1) RS49997B (de)
RU (1) RU2238273C2 (de)
SK (1) SK284339B6 (de)
TR (1) TR200102403T2 (de)
TW (1) TWI222975B (de)
UA (1) UA61164C2 (de)
UY (1) UY26048A1 (de)
WO (1) WO2000053608A1 (de)
ZA (1) ZA200106811B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0312297A (pt) 2002-07-18 2005-04-12 Cytos Biotechnology Ag Conjugados veìculos de hapteno e seu uso
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
EP1581223B2 (de) * 2002-12-06 2016-05-25 The Feinstein Institute for Medical Research Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
JP5701607B2 (ja) * 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
JP5645217B2 (ja) 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 5,6−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0820668A2 (pt) * 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
CA3017886A1 (en) 2008-11-19 2010-05-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX2011011972A (es) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa.
EP2435080A2 (de) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmazeutische zusammensetzungen zur schmerzbehandlung
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
AU744368B2 (en) * 1997-05-30 2002-02-21 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
RU2238273C2 (ru) 2004-10-20
CO5160250A1 (es) 2002-05-30
MXPA01008972A (es) 2002-03-27
CZ20013102A3 (cs) 2002-01-16
HK1040398B (zh) 2003-07-18
CA2372063C (en) 2011-01-11
TR200102403T2 (tr) 2001-12-21
KR100768355B1 (ko) 2007-10-17
TWI222975B (en) 2004-11-01
EP1161434B1 (de) 2003-01-29
WO2000053608A1 (fr) 2000-09-14
UA61164C2 (uk) 2003-11-17
ATE231869T1 (de) 2003-02-15
EE04497B1 (et) 2005-06-15
ZA200106811B (en) 2002-08-19
RS49997B (sr) 2008-09-29
CN1137894C (zh) 2004-02-11
DE60001307T2 (de) 2003-12-11
CZ302259B6 (cs) 2011-01-19
NO20014270L (no) 2001-11-05
NO327119B1 (no) 2009-04-27
BR0008763A (pt) 2002-01-02
JP4806123B2 (ja) 2011-11-02
AR022820A1 (es) 2002-09-04
KR20070086359A (ko) 2007-08-27
US6908927B2 (en) 2005-06-21
ID30116A (id) 2001-11-08
EE200100470A (et) 2002-12-16
ES2191611T3 (es) 2003-09-16
EP1161434A1 (de) 2001-12-12
IL145150A0 (en) 2002-06-30
BG105828A (bg) 2002-03-29
UY26048A1 (es) 2000-09-29
KR20010102492A (ko) 2001-11-15
US6538003B1 (en) 2003-03-25
IL145150A (en) 2007-06-03
US20030187012A1 (en) 2003-10-02
AU764625B2 (en) 2003-08-28
HK1040398A1 (en) 2002-06-07
DK1161434T3 (da) 2003-05-26
PE20001543A1 (es) 2001-03-18
NO20014270D0 (no) 2001-09-03
FR2790474A1 (fr) 2000-09-08
PL201683B1 (pl) 2009-04-30
HUP0201753A2 (en) 2002-09-28
NZ513561A (en) 2003-06-30
JP2002539129A (ja) 2002-11-19
SK284339B6 (sk) 2005-02-04
CA2372063A1 (en) 2000-09-14
HRP20010655A2 (en) 2002-08-31
SK12422001A3 (sk) 2002-04-04
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
FR2790474B1 (fr) 2001-04-06
HUP0201753A3 (en) 2004-12-28
CN1343208A (zh) 2002-04-03
HRP20010655B1 (en) 2003-06-30
PL352330A1 (en) 2003-08-11
HU228671B1 (en) 2013-05-28
YU59601A (sh) 2004-03-12

Similar Documents

Publication Publication Date Title
DE60001307T2 (de) Pyridopyranoazepinderivate, ihre herstellung und therapeutische verwendung
ATE284886T1 (de) Benzimidazolderivate, ihre herstellung und therapeutische verwendung
DE60001451D1 (de) 1,4-diazabicyclo[3.2.2]nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
DE50015711D1 (de) In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
ATE258549T1 (de) Oxazolidindion-derivate, ihre herstellung und verwendung
ATE332294T1 (de) Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung
DE10084441T1 (de) Koalinton-Pigmente, ihre Herstellung und Verwendung
DE60103394D1 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
DE60103054D1 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
NO20022021D0 (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, fremstilling av de samme og deres anvendelse somanoreksilegemidler
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
ATE242197T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
ATE533768T1 (de) Imidazol-derivate, ihre herstellung und ihre verwendung
DE60006958T2 (de) Streptograminderivate, ihre herstellung und sie enthaltende zubereitungen
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
ATE212346T1 (de) 3-substituierte tetrahydropyridopyrimidinon- derivate, ihre herstellung und verwendung
DE60144456D1 (de) DibenzoÄb,fÜazepin-Derivate und ihre Herstellung
ATE236905T1 (de) 4-oxo-3,5-dihydro-4h-pyridazino(4,5-b)indol-1- carboxamid-derivate, ihre herstellung und therapeutische verwendung
ATE184005T1 (de) Oxazolidinone derivate, ihre herstellung und ihre therapeutische verwendung
ATE249451T1 (de) Benzofuranderivate, ihre herstellung und verwendung
DE59501950D1 (de) Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
ATE198192T1 (de) Benzolsulfonamidderivate, ihre herstellung und ihre therapeutische verwendung
ATE263138T1 (de) 3-amino-3-arylpropan-1-ol-derivate, deren herstellung und verwendung
DE60203791D1 (de) Imidazolin-derivate, ihre herstellung und ihre verwendung als entzündungshemmende mittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

R082 Change of representative

Ref document number: 1161434

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE